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Abstract
There are unprecedented epidemics of obesity, such as type II diabetes and non-alcoholic
fatty liver diseases (NAFLD) in developed countries. A concerning percentage of American
children are being affected by obesity and NAFLD. Studies have suggested that the mater-
nal environment in uteromight play a role in the development of these diseases later in life.
In this study, we documented that inhibiting SIRT1 signaling in human fetal hepatocytes rap-
idly led to an increase in intracellular glucose and lipids levels. More importantly, both de
novo lipogenesis and gluconeogenesis related genes were upregulated upon SIRT1 inhibi-
tion. The AKT/FOXO1 pathway, a major negative regulator of gluconeogenesis, was
decreased in the human fetal hepatocytes inhibited for SIRT1, consistent with the higher
level of gluconeogenesis. These results indicate that SIRT1 is an important regulator of lipid
and carbohydrate metabolisms within human fetal hepatocytes, acting as an adaptive tran-
scriptional response to environmental changes.
Introduction
SIRT1 (Silent mating type information regulation 2 homolog) belongs to the Sirtuins family of
proteins and codes for a class III NAD-dependent histone deacetylase (HDACs). In mammals,
the functions of SIRT1 have been essentially linked to the regulation of growth, apoptosis,
metabolism and aging, responding to environmental cues through NAD+ levels [1–4]. SIRT1
deacetylates a wide range of targets, leading to epigenetic modifications of histones and modu-
lation of transcription factors or metabolic enzymes [3]. Thus, SIRT1 has been thought to be a
molecular link between the adaptive transcriptional response and the metabolic status [5, 6].
Recent studies performed on the liver of mice showed the key role of SIRT1 in the development
of fatty liver through the regulation of proteins involved in lipid [7, 8] and carbohydrate
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metabolism [9–11]. These studies have highlighted the potential therapeutic use of SIRT1 in
hepatic steatosis.
In recent years, the incidence of non-alcoholic fatty liver diseases (NAFLD) has increased
dramatically in developed countries, present in more than 30% of the population in the U.S. It
is associated with obesity, insulin resistance, and type II diabetes, and it predisposes the liver to
the development of chronic inflammation and oxidative stress [12]. Nonalcoholic steatohepati-
tis or NASH is the combination of fatty infiltration of hepatocytes with the presence of inflam-
mation. Ballooning degeneration of hepatocytes and increased Mallory’s hyaline inclusions
often manifests this injury. Progressive inflammation in both pediatric and adult NASH
patients can lead to scarring or fibrosis of the liver and, in severe cases, even cirrhosis and hepa-
tocellular carcinomas (HCC). More importantly, pediatric liver steatosis has increased dramat-
ically in the last 10 years, affecting more than 10% of American children [13]. Pediatric
NAFLD is strongly associated with obesity and insulin resistance and its pathogenesis is not yet
fully understood [14]. Most worrying is the fact that cardiovascular morbidity in children and
teenagers are associated with NAFLD. Thus, understanding the pathogenesis, risk factors, and
natural history of fatty liver disease is much needed to prevent youth at risk.
The role played by the environment in the development of NAFLD is very important despite
potential genetic susceptibilities. Nicholas Hales and David Barker have proposed the “Thrifty phe-
notype hypothesis”, which speculate that the maternal nutrition during development may lead to
type 2 diabetes, obesity, and the metabolic syndrome in the offspring later in life [15]. There have
been several demonstrations of this “fetal origin of adult disease” in rodent models, testing the
effect of caloric restriction or high fat diet on the first and second generations of offspring [16–19].
However, only few indications of such demonstrations have been observed in human [20, 21],
thus, when and how the human body becomes susceptible to this environment remains unknown.
Herein, we have investigated the role of SIRT1 in the lipid and carbohydrate metabolisms of
human fetal hepatocytes and showed that a short-span inhibition of this protein lead to an upregu-
lation of de novo lipogenesis and gluconeogenesis pathways in human fetal hepatocytes.
Material and Methods
Fetal human hepatocytes isolation and culture
The de-identified tissues were obtained fromMagee Women’s Hospital (Pittsburgh, PA) and
the University of Washington Department of Pediatrics, Division of Genetic Medicine, Labora-
tory of Developmental Biology (Seattle, WA) after obtaining a written informed consent by a
protocol approved by the Human Research Review Committee of the University of Pittsburgh
(Honest broker approval number HB015 and HB000836). Human fetal hepatocytes were iso-
lated from fetal livers (Table 1) obtained after the termination of pregnancy performed at 20–
23 weeks of gestation. Primary human fetal hepatocytes were isolated by digesting the tissue in
Table 1. Donor Demographics.
Tissue ID Gestational age Sex Viability
Fetal liver 1 20 weeks Male 87%
Fetal liver 2 20 weeks Female 88%
Fetal liver 3 21 weeks Unknown 88%
Fetal liver 4 23 weeks Female 88%
Fetal liver 5 21 weeks Male 89%
Fetal liver 6 23 weeks Female 91%
Fetal liver 7 21 weeks Female 87%
Fetal liver 8 20 weeks Male 88%
doi:10.1371/journal.pone.0149344.t001
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EMEM (Lonza, Walkersville, MD), which contains 0.5 mg/ml of collagenase (Type XI, Sigma-
Aldrich, Saint-Louis MO, Cat. #C7657), on a lab shaker for 40 minutes. Viability was assessed
by trypan blue exclusion test and was routinely>85%. Fetal hepatocytes were plated at a den-
sity of 1.3x105 cells/cm2 on type I rat tail collagen coated 12 well plates (Corning, Corning,
NY). Cells were cultured for 3 days with a DMEMmedium (Gibco, Life Technologies, Carls-
bad, CA, USA) containing 1X penstrep, 10-7M of insulin (Sigma-Aldrich, Saint-Louis, MO),
and 5% bovine serum albumin (Gibco, Life Technologies, Carlsbad, CA, USA). The SIRT1
pharmacological inhibitor (Sirtinol) was purchased from Chayman Chemical (Ann Arbor, MI,
USA) and was added to the cells at a concentration of 50uM every 24h from day 0 to 3.
RNA extraction, Reverse Transcription and quantitative Polymerase
Chain Reactions
Total RNA from the cultured human fetal hepatocytes were extracted using the RNeasy mini kit
(Qiagen, Valencia, CA, USA) using the manufacturer's protocol. RNA was quantified by a spec-
trophotometer to assess the chemical purity and concentration of RNA. 2ug of RNA was mixed
with random hexamers (Invitrogen, Carlsbad, CA), heated to 70°C for 5 minutes, and cooled to
4°C. RNA was then reverse transcribed using the Superscript III First-Strand Synthesis System
(Invitrogen, Carlsbad, CA), following the manufacturer's protocol. Subsequently, qPCR was per-
formed using TaqMan Fast AdvancedMaster Mix (Life Technologies, CA, USA) with a StepOne-
Plus system (Applied Biosystems, Foster City, CA) with the primers from Life Technologies
(Carlsbad, CA, USA) described in Table 2. Expression of specific genes was normalized to an
internal control Hypoxanthine-guanine phosphoribosyltransferase (HPRT) mRNA expression.
Metabolic content measurement
Cultured human fetal hepatocytes were washed with PBS and fixed with 4% PFA for 20min.
Cells were stained with HCS LipidTOX red neutral lipid stain and Hoechst 33342 (Sigma-
Aldrich, Saint-Louis, MO) for 30 min following the manufacturer's protocol. Triglycerides
were extracted from fetal hepatocytes by mixing 10% of NP-40 to the cell pellets and by incu-
bating at 80°C for 5min. The triglycerides were measured with a Triglyceride Quantification
colorimetric assay (Biovision, Milpitas, CA) according to the manufacturer's instructions. Glu-
cose concentration levels were measured from fetal hepatocytes medium by using the glucose
autokit (Wako Chemicals, Richmond, VA).
Table 2. List Primers.
Gene Name Gene Symbol Reference (Life technologies)
acetyl-CoA carboxylase alpha ACACA Hs01046047_m1
ELOVL fatty acid elongase 6 ELOVL6 Hs00907564_m1
fatty acid synthase FASN Hs01005622_m1
glucose-6-phosphatase, catalytic subunit G6PC Hs02560787_s1
hypoxanthine phosphoribosyltransferase 1 HPRT1 Hs02800695_m1
phosphoenolpyruvate carboxykinase 2 PCK2 Hs00388934_m1
stearoyl-CoA desaturase SCD Hs01682761_m1
sirtuin 1 SIRT1 Hs01009006_m1
sterol regulatory element binding transcription factor 1 SREBF1 Hs01088691_m1
acyl-CoA dehydrogenase ACADM Hs00936580_m1
acyl-CoA oxidase 1 ACOX1 Hs01074241_m1
ATP-binding cassette, sub-family A (ABC1), member 1 ABCA1 Hs01059118_m1
doi:10.1371/journal.pone.0149344.t002
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Histological assessment
Cultured human fetal hepatocytes were washed with PBS and fixed with 4% PFA for 20min.
Incubations with primary antibodies (1:100 mouse anti-SIRT1, (Santa Cruz Biotechnology #sc-
74504), 1:100 rabbit anti-phospho Ser473-Akt (Cell signaling #4060) and 1:400 rabbit anti-
phospho Ser256-FOXO1 (Abcam #ab26651)) were carried out overnight at 4°C. For the detec-
tion of the primary antibodies, secondary antibodies (1:250 Alexa Fluor 488 Donkey anti-
Mouse IgG (Life technologies CA, USA #A-21202), and 1:250 Alexa Fluor 488 Goat anti-Rab-
bit IgG (Life technologies, CA, USA #A-11008)) were used followed by counterstaining with
0.2 ug/mL of Hoechst 33342 (Sigma-Aldrich, Saint-Louis, MO). Images were captured using a
Zeiss microscope. Acquired images were processed and quantified using ImageJ 1.48v
software.
Western Blot
A total of 30 μg of protein was resolved on Tris-HCl precast gels (Bio-Rad Laboratories, Hercu-
les, CA) by SDSPAGE analysis. The proteins were transferred to polyvinylidene difluoride
membranes. Membranes were incubated overnight at 4°C with the following primary antibod-
ies: Mouse anti-SIRT1 sc-74504, Rabbit anti-glyceraldehyde-3-phosphate dehydrogenase sc-
2577 (Santa Cruz Biotechnology, Santa Cruz, CA), Rabbit Akt #4691S, Rabbit Phospho-Akt-
ser473#4060 (Cell signaling, Beverly, MA), Rabbit anti-FOXO1 ab70382, Rabbit Phospho-
FOXO1-Ser256 ab26651, Mouse TORC2 ab105932 (Abcam, Cambridge, MA). The signal was
amplified either by an anti-mouse or anti-rabbit HRP-conjugated secondary antibody (Milli-
pore, Billerica, MA). Proteins were revealed using the SuperSignal West Pico Chemilumines-
cent Substrate (Thermo Fisher Scientific, San Jose, CA).
Statistical analyses
All statistical analyses were performed with Prism 6.0 Software (GraphPad Software, Inc., La
Jolla, CA) using non-parametric Mann-Whitney test. Data were presented as mean ± SEM,
with P< 0.05 considered as statistically significant.
Results
Inhibition of SIRT1 induces an increase in lipids and carbohydrates
levels in human fetal hepatocytes
There are numerous studies that address the role of SIRT1 in liver metabolism [8, 22–24]. In
mice, it has been shown that the deletion of SIRT1 leads to hepatic steatosis with normal and
high fat diet [7, 22]. Moreover, mice models of hepatic steatosis display low levels of SIRT1
[25]. Both the metabolism of carbohydrates and lipids were found to be upregulated in these
models. The expression of SIRT1 in adult liver has been described, however, SIRT1 expression
and role in human fetal hepatocytes is unknown. Thus, we first assessed the expression of
SIRT1 in human fetal hepatocytes. Immune-staining of SIRT1 in fetal and adult liver tissue
demonstrated that SIRT1 is expressed in both tissues (Fig 1A). Immune-histological images of
adult and fetal hepatocytes in culture also exhibited a clear expression of SIRT1, mainly cyto-
plasmic with some nuclear localization (Fig 1B). This was further confirmed by western blot
analysis of SIRT1 in human fetal hepatocytes (S1 Fig) and with qPCR analysis of SIRT1 expres-
sion (Fig 1B). These results strongly indicate that SIRT1 is highly expressed during develop-
ment in human fetal hepatocytes.
To characterize the role of SIRT1 in lipid and glucose metabolism of human fetal hepato-
cytes, we used a pharmacological inhibitor of SIRT1, Sirtinol. Human fetal hepatocytes were
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exposed to 50uM of Sirtinol for three days. Intracellular lipid accumulation was analyzed using
a fluorescent probe (Fig 2A). As expected, normal human fetal hepatocytes exhibit almost no
intracellular lipid. However, we observed a clear increase in intracellular lipid accumulation
when SIRT1 was inhibited. This was further confirmed by measuring the intracellular triglycer-
ides. Human fetal hepatocytes exposed to Sirtinol showed a 30-fold increase in triglycerides
accumulation compared to control (Fig 2B). We then measured the intracellular glucose levels.
Human fetal hepatocytes inhibited for SIRT1 exhibited a significantly higher level of glucose
concentration compared to control (Fig 2C). Altogether, these results showed that Sirtinol
exposure leads to an increase in lipid and glucose levels in human fetal hepatocytes after SIRT1
inhibition.
Fig 1. Expression of SIRT1 in human fetal and adult liver and isolated hepatocytes. (A) Immunohistochemistry of SIRT1 in human fetal and adult liver,
(B) Immunofluorescence staining of SIRT1 in fetal and adult hepatocytes after 2 days of culture. (C) Quantification of hepatic SIRT1 mRNA expression
measured by qRT- PCR in human fetal and adult hepatocytes in vitro and in vivo (n3/group).
doi:10.1371/journal.pone.0149344.g001
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Inhibition of SIRT1 leads to an increased de novo lipogenesis in human
fetal hepatocytes
Two potential pathways could explain the increase in lipid content after SIRT1 inhibition: a
decrease in β-oxidation and increase in de novo lipogenesis pathway. We examined the mRNA
levels of two gene targets of β-oxidation, acyl-CoA dehydrogenase (ACADM) and acyl-CoA oxi-
dase 1 (ACOX1). We could not detect any difference between human fetal hepatocytes with or
without Sirtinol (S2A Fig). This can be explained by previous findings reporting that β-oxidation
of fetal livers is low. Shortly after birth, exposure of fatty acids through the mother’s milk induces
the activation β-oxidation through CPT1-a [26]. Moreover, SIRT1 liver inhibition in rodents has
been shown to induce an increase in de novo lipogenesis, leading to hepatic steatosis [7]. Thus,
we studied genes involved in de novo lipogenesis by performing qPCR 24h after Sirtinol exposure.
We found that all four major genes involved in de novo—fatty acid synthase (FAS), acetyl-CoA
carboxylase (ACC), stearoyl-CoA desaturase (SCD), and elongase of long chain fatty acids family
6 (ELOVL6)—were upregulated when the cells were exposed to SIRT1 inhibitor (Fig 3A, 3B, 3C
and 3D). These findings are very consistent with previous published data showing an increase in
de novo lipogenesis associated with SIRT1 inhibition in rodents [7] and explain the rapid increase
in lipid production and accumulation of human fetal hepatocytes.
Inhibition of SIRT1 leads to an increased gluconeogenesis in human
fetal hepatocytes through the impairment of AKT/FOXO1 pathway
Previous studies have reported controversial results regarding changes in glucose production
and use in rodent models with SIRT1-knockout [10, 11]. More recently, we reported that
rodents carrying a liver-SIRT1 knockout exhibited hyperglycemia and had an increase in glu-
coneogenesis, which lead to insulin resistance [9]. Herein, we first investigated gluconeogenesis
Fig 2. Lipids and glucose levels in human fetal hepatocytes after Sirt1 inhibition. (A) Fluorescent staining of lipids (red droplets, white arrow) inside
human fetal hepatocytes (HFH) with or without 50uM Sirtinol for 3 days (20x). (B) Triglycerides quantification of human fetal hepatocytes with or without
+50uM Sirtinol for 3 days analyzed by a colorimetric assay. (C) Glucose concentration between normal HFH and HFH +50uM Sirtinol for 3 days. (n7/group;
*, P < .05).
doi:10.1371/journal.pone.0149344.g002
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in human fetal hepatocytes by measuring the transcript of two main gluconeogenetic enzymes:
phosphoenolpyruvate carboxykinase (PEPCK) and the catalytic subunit of glucose-6-phospha-
tase (G6Pc). Both exhibited approximately 3-fold increases, which was consistent with the
increase in glucose concentration observed (Fig 4A). Inside the liver, the gluconeogenesis path-
way is known to be under the control of AKT/FOXO1 [27]. Forkhead box O1 (FOXO1) usually
enters the nucleus and eventually leads to the activation of genes linked to gluconeogenesis.
However, the activation of AKT induces the phosphorylation of FOXO1, which lead to the
exclusion of this protein out of the nucleus to the cytoplasm. This system controls the level of
gluconeogenesis inside the cell [27]. Thus, to further explain the upregulaltion of the gluconeo-
genesis pathway, we first checked the activation of AKT at serine 473 through immunofluores-
cence staining of human fetal hepatocytes. AKT phosphorylation was found in both cells, but
to a lower extend when Sirtinol was present (Fig 4B and 4C). Western blots analysis corrobo-
rated the decrease of AKT-S473 activation in human fetal hepatocytes inhibited for SIRT1 (Fig
4D). We then measured the phosphorylation of FOXO1, downstream of AKT. FOXO1 S256
decreases in human fetal hepatocytes with Sirtinol, which indicate a higher FOXO1 activity
inside the nucleus (Fig 4D). As expected, immunofluorescence staining of FOXO S256 exhib-
ited a cytoplasmic localization of the protein in both groups of human fetal hepatocytes (Fig
4E). Overall, these data demonstrates that the inhibition of SIRT1 causes an increase in gluco-
neogenesis, leading to a higher intracellular glucose concentration in human fetal hepatocytes,
through the control of AKT/FOXO1 pathway.
Fig 3. Increased activation of De Novo Lipogenesis related genes in human fetal hepatocytes after Sirt1 inhibition. Expression of hepatic FASN,
SCD, ACC and ELOVL6 mRNAmeasured by qRT-PCR in human fetal hepatocytes exposed to +50uM Sirtinol compared to controls. (N7/group; *, P < .05)
doi:10.1371/journal.pone.0149344.g003
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Discussion
In the recent years, researchers have just started exploring and understanding the importance
of SIRT1 in metabolism. SIRT1 acts as a metabolic “switch” linked to hepatic steatosis. To the
best of our knowledge, this is the first report that showed the implication of SIRT1 in metabolic
processes in human fetal hepatocytes. In this study, we observed that the inhibition of SIRT1
using a pharmacological agent for a short period of time leads to a rapid increase in lipid and
carbohydrate concentrations. Moreover, we have confirmed a negative regulation of SIRT1 in
de novo lipogenesis and gluconeogenesis through the AKT/FOXO1 pathway in human fetal
hepatocytes. These results are coherent with previously studies on mice carrying a deletion of
SIRT1 in the liver and developing liver steatosis. These results also show that human fetal hepa-
tocytes are responsive to SIRT1 signals and emphasize SIRT1 role as a regulator of lipid and
Fig 4. Increased activation of Glucogenesis pathway in human fetal hepatocytes after exposure to Sirtinol. (A) Expression of hepatic PEPCK and
G6PCmRNAmeasured by qRT- PCR in human fetal hepatocytes exposed to +50uM Sirtinol compared to controls. (B) Immunofluorescence of S-473 AKT in
human fetal hepatocytes with or without 50uM Sirtinol (10x). (C) Fluorescence intensity quantification for S-473 AKT signal (arbitrary units) using ImageJ
(n7/group; *, P < .05). (D) Western blot analysis for S-473 AKT/AKT, S-256 FOXO1/FOXO1 in human fetal hepatocytes exposed to 50uM Sirtinol
compared to controls. GAPDHwas used as a loading control. (E) Immunofluorescence staining of S-256 FOXO1 in human fetal hepatocytes with or without
50uM Sirtinol (20x).
doi:10.1371/journal.pone.0149344.g004
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glucose balances in the liver (Fig 5). Altogether, this study confirmed the extensive role of
SIRT1 in hepatocytes metabolism during development.
Previous studies have already documented an increase in lipogenesis and gluconeogenesis
during fetal development [28, 29]. The maternal diet (fructose diet and high fat diet) imposed
these metabolic changes on the fetus. It suggests that changes in the maternal diet can provide
more nutrients availability, used as energy blocks by the fetus to sustain these metabolic path-
ways. Similarly, exposure to certain factors (such as a high fat diet) might affect SIRT1 in the
liver and induce metabolic changes during development. In the long run (after birth), an
increase production of lipids could render these offsprings more susceptible to the develop-
ment of hepatic steatosis and hence hyperglycemia that is linked to insulin resistance and dia-
betes [30, 31]. Consequently, more sophisticated models to study human tissues overtime
(infants and adults) are needed to address questions regarding the important role of SIRT1 and
the molecular mechanistic upstream and downstream.
Our future studies will investigate which signaling pathways under SIRT1 influence the
lipid metabolism on these cells. For instance, SIRT1 has been shown to deacetylate Liver X
Receptor (LXR), which is a regulator of lipid homeostasis [32]. However, we were not able to
detect differences in LXR gene targets: ATP-binding cassette, sub-family A (ABC1), member 1
or Srebp-1c (S2B Fig). This suggests that SIRT1 may acts through another pathway in human
fetal hepatocytes. In the other hand, AKT/FOXO1 pathway is a major regulator of glucose pro-
duction in response to insulin, nevertheless, it has been shown that SIRT1 represses gluconeo-
genesis during fasting, through CREB-regulated transcription coactivator 2 (CRTC2)
deacetylation, leading to its degradation [33]. However, we did not find significant changes in
CRTC2 expression when SIRT1 was inhibited (S2C Fig). These results support the main role of
AKT/FOXO1 pathway to regulate gluconeogenesis under the control of SIRT1 in human fetal
hepatocytes.
Fig 5. Representation of SIRT1 regulation of lipid and glucose balances in human fetal hepatocytes. In normal conditions, SIRT1 inhibits De Novo
Lipogenesis and Gluconeogenesis through the AKT/FOXO1 pathway inside human fetal hepatocytes, keeping a normal balance inside the cells. Upon
SIRT1 inhibition, both the lipid and glucose balance will be disrupted, leading to an increase of lipid and carbohydrates levels in human fetal hepatocytes.
doi:10.1371/journal.pone.0149344.g005
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Numerous rodent studies have shown that the parental dietary may affect the development
of diseases later in life, such as diabetes or obesity, by changing the epigenetic signature of the
offspring [34]. Recently, studies performed on animal models reported that maternal high fat
diet and obesity resulted in a decrease of SIRT1 mRNA in fetal livers [35, 36], highlighting the
role of intrauterine environment on SIRT1 expression. However, animal models do not mimic
the pathogenesis of human metabolic diseases and further studies on human tissues will be
required to determine what controls SIRT1. It will be interesting to determine whether SIRT1
acts as an adaptive transcriptional response during human development. In this respect, SIRT1
could respond to external environmental cues such as maternal obesity and create the condi-
tions to develop NAFLD. A better understanding of the central position of SIRT1 in hepatic
metabolism will help in the comprehension of the metabolic diseases and will provide valuable
information to prevent and treat human metabolic abnormalities.
Supporting Information
S1 Fig. Expression of SIRT1 in fetal liver cells.Western blot analysis of SIRT1 in human fetal
liver cells (fibroblasts and hepatocytes). A human fetal fibroblasts cell line carrying a shMIR--
SIRT1 activated upon doxycycline addition was used to assess the specificity of SIRT1 expres-
sion.
(TIF)
S2 Fig. Analysis of alternative β-oxidation, lipogenesis and gluconeogenesis related genes.
(A) Expression of hepatic ACOX1 and ACADMmRNAmeasured by qRT- PCR in human
fetal hepatocytes exposed to +50uM Sirtinol compared to controls. (B) Expression of hepatic
ABCA1 and SREBP-1C mRNA expression measured by qRT- PCR in human fetal hepatocytes
exposed to +50uM Sirtinol compared to controls. (n7/group; , P< .05) (C) Western blot
analysis for CRCT2 in human fetal hepatocytes exposed to +50uM Sirtinol. GAPDH was used
as a control.
(TIF)
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